Show simple item record

Article

dc.creatorRemon, Jordies
dc.creatorGirard, Nicolases
dc.creatorNovello, Silvia;es
dc.creatorCastro, Javier dees
dc.creatorBigay-Game, Laurencees
dc.creatorBernabé, Reyeses
dc.creatorBesse, Benjamines
dc.date.accessioned2022-11-07T17:41:59Z
dc.date.available2022-11-07T17:41:59Z
dc.date.issued2022
dc.identifier.issn1525-7304es
dc.identifier.issn1938-0690es
dc.identifier.urihttps://hdl.handle.net/11441/139098
dc.description.abstractThymic epithelial tumors are rare neoplastic proliferations of thymic epithelial cells. The aggressiveness of these malignancies increases as higher is the histologic subtype, being thymic carcinoma the most aggressive subtype, with a greater tendency to metastatic spread. In metastatic setting, there is no standard treatment after progression on platinum-based chemotherapy. In this scenario, monotherapy treatment either with lenvatinib, a multi-tyrosine kinase inhibitor with antiangiogenic properties, or pembrolizumab, an immune-checkpoint inhibitor, has reported clinical activity. Potential combination of both agents may have synergistic activity as reported in other cancer types. PECATI trial is a single-arm, investigator-initiated phase II study aiming to assess the activity and safety of the combination of lenvatinib and pembrolizumab in 43 patients with advanced B3-thymoma or thymic carcinoma who progressed on or after at least one previous line of platinum-based chemotherapy. The primary endpoint of the trial is 5-month progression-free survival rate and the secondary endpoints include overall response rate, duration of response, and overall survival.es
dc.formatapplication/pdfes
dc.format.extent4es
dc.language.isoenges
dc.publisherElsevieres
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectThymic epithelial tumorses
dc.subjectImmunotherapyes
dc.subjectSecond-linees
dc.subjectPembrolizumabes
dc.subjectLenvatinibes
dc.titlePECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patientses
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttp://doi.org/10.1016/j.cllc.2021.07.008es
dc.identifier.doi10.1016/j.cllc.2021.07.008es
dc.journaltitleClinical Lung Canceres
dc.publication.volumen23es
dc.publication.issue3es
dc.publication.initialPagee243es
dc.publication.endPagee246es

FilesSizeFormatViewDescription
357.pdf342.2KbIcon   [PDF] View/Open  

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as: Attribution-NonCommercial-NoDerivatives 4.0 Internacional